Immunomedics, Inc. (Nasdaq: IMMU ), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that small, repeated doses of epratuzumab labeled with the radioisotope, yttrium-90 (^90Y), demonstrated therapeutic activity in 2 clinical trials in patients with aggressive non-Hodgkin